224 related articles for article (PubMed ID: 1936476)
1. The effects of oral hypoglycaemic drugs on serum lipids and lipoproteins in non-insulin-dependent diabetes (NIDDM).
Elkeles RS
Diabete Metab; 1991 May; 17(1 Pt 2):197-200. PubMed ID: 1936476
[TBL] [Abstract][Full Text] [Related]
2. Effects of metformin and glibenclamide alone and in combination on serum lipids and lipoproteins in patients with non-insulin-dependent diabetes mellitus.
Hermann LS; Kjellström T; Nilsson-Ehle P
Diabete Metab; 1991 May; 17(1 Pt 2):174-9. PubMed ID: 1936472
[TBL] [Abstract][Full Text] [Related]
3. Effects of metformin on glucose, insulin and lipid metabolism in patients with mild hypertriglyceridaemia and non-insulin dependent diabetes by glucose tolerance test criteria.
Hollenbeck CB; Johnston P; Varasteh BB; Chen YD; Reaven GM
Diabete Metab; 1991; 17(5):483-9. PubMed ID: 1752350
[TBL] [Abstract][Full Text] [Related]
4. Effects of glibenclamide on serum lipids, lipoproteins, thromboxane, beta-thromboglobulin, and prostacyclin in non-insulin-dependent diabetes mellitus.
Waysbort J; Regitz G; Chaimowitz D; Tuval M; Nakash I; Brunner D
Clin Ther; 1988; 10(4):358-71. PubMed ID: 2978874
[TBL] [Abstract][Full Text] [Related]
5. The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia.
Comaschi M; Corsi A; Di Pietro C; Bellatreccia A; Mariz S;
Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):373-9. PubMed ID: 17919894
[TBL] [Abstract][Full Text] [Related]
6. The effect of glibenclamide and metformin on serum lipoproteins in type 2 diabetes.
Rains SG; Wilson GA; Richmond W; Elkeles RS
Diabet Med; 1988 Oct; 5(7):653-8. PubMed ID: 2975549
[TBL] [Abstract][Full Text] [Related]
7. Lipid profile and its relation to fasting insulin level in non-insulin dependent diabetes mellitus (NIDDM).
Uddin F; Miah AK
Bangladesh Med Res Counc Bull; 1995 Aug; 21(2):64-72. PubMed ID: 8815864
[TBL] [Abstract][Full Text] [Related]
8. Effects of a gel forming dietary fiber, guar gum, on the absorption of glibenclamide and metabolic control and serum lipids in patients with non-insulin-dependent (type 2) diabetes.
Uusitupa M; Södervik H; Silvasti M; Karttunen P
Int J Clin Pharmacol Ther Toxicol; 1990 Apr; 28(4):153-7. PubMed ID: 2110937
[TBL] [Abstract][Full Text] [Related]
9. Combined metformin and insulin therapy for patients with type 2 diabetes mellitus.
Ponssen HH; Elte JW; Lehert P; Schouten JP; Bets D
Clin Ther; 2000 Jun; 22(6):709-18. PubMed ID: 10929918
[TBL] [Abstract][Full Text] [Related]
10. Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes.
Tan MH; Johns D; Strand J; Halse J; Madsbad S; Eriksson JW; Clausen J; Konkoy CS; Herz M;
Diabet Med; 2004 Aug; 21(8):859-66. PubMed ID: 15270789
[TBL] [Abstract][Full Text] [Related]
11. Effects of glyburide treatment on serum lipoprotein and apolipoprotein concentrations and ratios in non-insulin-dependent diabetes mellitus.
Waysbort J; Regitz G; Brunner D
Clin Ther; 1988; 10(4):392-400. PubMed ID: 3152618
[TBL] [Abstract][Full Text] [Related]
12. Comparative efficacy of metformin and glibenclamide in patients with non-insulin-dependent diabetes mellitus.
Hermann LS; Bitzén PO; Kjellström T; Lindgärde F; Scherstén B
Diabete Metab; 1991 May; 17(1 Pt 2):201-8. PubMed ID: 1936477
[TBL] [Abstract][Full Text] [Related]
13. Comparison of lipid profiles and lipoprotein a levels in patients with type 2 diabetes mellitus during oral hypoglycemic or insulin therapy.
Habib SS; Aslam M; Naveed AK; Razi MS
Saudi Med J; 2006 Feb; 27(2):174-80. PubMed ID: 16501671
[TBL] [Abstract][Full Text] [Related]
14. Prospective comparative study in NIDDM patients of metformin and glibenclamide with special reference to lipid profiles.
Hermann LS; Karlsson JE; Sjöstrand A
Eur J Clin Pharmacol; 1991; 41(3):263-5. PubMed ID: 1748145
[TBL] [Abstract][Full Text] [Related]
15. Effect of N-benzoyl-D-phenylalanine on streptozotocin-induced changes in the lipid and lipoprotein profile in rats.
Ashokkumar N; Pari L; Manimekalai A; Selvaraju K
J Pharm Pharmacol; 2005 Mar; 57(3):359-66. PubMed ID: 15807992
[TBL] [Abstract][Full Text] [Related]
16. The effect of metformin on glycemic control, serum lipids and lipoproteins in diet alone and sulfonylurea-treated type 2 diabetic patients with sub-optimal metabolic control.
Mughal MA; Jan M; Maheri WM; Memon MY; Ali M
J Pak Med Assoc; 2000 Nov; 50(11):381-6. PubMed ID: 11126815
[TBL] [Abstract][Full Text] [Related]
17. The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.
Robinson AC; Burke J; Robinson S; Johnston DG; Elkeles RS
Diabetes Care; 1998 May; 21(5):701-5. PubMed ID: 9589227
[TBL] [Abstract][Full Text] [Related]
18. Effect of bezafibrate on metabolic profiles in non-insulin-dependent diabetes mellitus.
Alberti KG; Jones IR; Laker MF; Swai AB; Taylor R
J Cardiovasc Pharmacol; 1990; 16 Suppl 9():S21-4; discussion S24-5. PubMed ID: 1710741
[TBL] [Abstract][Full Text] [Related]
19. Effect of oral antidiabetic agents on plasma amylin level in patients with non-insulin-dependent diabetes mellitus (type 2).
Zapecka-Dubno B; Czyzyk A; Dworak A; Bak MI
Arzneimittelforschung; 1999 Apr; 49(4):330-4. PubMed ID: 10337452
[TBL] [Abstract][Full Text] [Related]
20. The reduction of low density lipoprotein cholesterol by metformin is maintained with long-term therapy.
Rains SG; Wilson GA; Richmond W; Elkeles RS
J R Soc Med; 1989 Feb; 82(2):93-4. PubMed ID: 2647992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
